# TuHURA Biosciences, Inc./NV

TuHURA Biosciences, Inc./NV is a public company listed on Nasdaq as HURA, headquartered in Tampa, FL, United States.

## Company overview

- **Legal name:** TuHURA Biosciences, Inc./NV
- **Former names in filing history:** Kintara Therapeutics, Inc. (2020-08-21 to 2024-10-22); DelMar Pharmaceuticals, Inc. (2013-01-23 to 2020-08-18); Berry Only Inc. (2010-08-17 to 2013-01-18)
- **Classification:** Public company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Tampa, FL, United States
- **Incorporated in:** NV
- **Fiscal year end:** December 31
- **Ticker:** Nasdaq: HURA
- **SEC CIK:** 0001498382

## About

TuHURA Biosciences, Inc./NV is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001498382, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2026-03-31, it reported annual revenue of USD 0; net income of USD -30,051,977; total assets of USD 27,353,156 for the fiscal period ended 2025-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2025 (period ended 2025-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$30.1M (USD -30,051,977)
- **Total assets:** $27.4M (USD 27,353,156)
- **Cash and equivalents:** $3.6M (USD 3,619,949)
- **Operating cash flow:** -$27.6M (USD -27,629,150)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$21.7M (USD -21,682,306)
- **Total assets:** $20.0M (USD 19,966,684)
- **Cash and equivalents:** $12.7M (USD 12,657,178)
- **Operating cash flow:** -$14.7M (USD -14,728,138)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2024 (period ended 2024-06-30)

- **Net income:** -$8.3M (USD -8,320,000)
- **Total assets:** $6.2M (USD 6,202,000)
- **Cash and equivalents:** $4.9M (USD 4,909,000)
- **Operating cash flow:** -$7.2M (USD -7,176,000)

### FY2023 (period ended 2023-06-30)

- **Net income:** -$14.6M (USD -14,649,000)
- **Total assets:** $4.0M (USD 3,979,000)
- **Cash and equivalents:** $1.5M (USD 1,535,000)
- **Operating cash flow:** -$11.9M (USD -11,865,000)

## Recent SEC filings

- Form 8-K — filed 2026-09-24 — period 2026-09-21 — 8-K
- Form 8-K — filed 2026-09-17 — period 2026-09-14 — 8-K
- Form 8-K — filed 2026-09-16 — period 2026-09-10 — 8-K
- Form 8-K — filed 2026-09-04 — period 2026-09-02 — 8-K
- Form 8-K — filed 2026-08-21 — period 2026-08-20 — 8-K
- Form 8-K — filed 2026-08-19 — period 2026-08-18 — 8-K
- Form 10-Q — filed 2026-08-14 — period 2026-06-30 — 10-Q
- Form 8-K — filed 2026-08-14 — period 2026-08-14 — 8-K
- Form 8-K — filed 2026-08-13 — period 2026-08-07 — 8-K
- Form 8-K — filed 2026-07-29 — period 2026-07-28 — 8-K
- Form DEF 14A — filed 2026-07-09 — period 2026-08-18 — DEF 14A
- Form 8-K — filed 2026-07-07 — period 2026-06-30 — 8-K

---

Updated: 2026-10-23T06:52:41Z

Canonical page: https://altss.com/profile/tuhura-biosciences-inc-nv

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology